Alto Neuroscience, Inc. (NYSE:ANRO) Stock Has Average Target Price of $37.25 According to Brokerages

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been given a consensus recommendation of “Moderate Buy” by the eleven research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $37.25.

A number of research analysts recently weighed in on ANRO shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, July 29th. HC Wainwright boosted their price objective on Alto Neuroscience from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. BTIG Research increased their target price on Alto Neuroscience from $28.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Wall Street Zen downgraded Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Finally, Wedbush raised their target price on Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th.

Alto Neuroscience Stock Performance

NYSE:ANRO opened at $27.19 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85. The company has a fifty day moving average of $31.20 and a two-hundred day moving average of $26.01. The stock has a market capitalization of $1.07 billion, a PE ratio of -11.23 and a beta of 1.13. Alto Neuroscience has a fifty-two week low of $3.77 and a fifty-two week high of $37.48.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.08. As a group, research analysts forecast that Alto Neuroscience will post -2.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Quantinno Capital Management LP grew its position in shares of Alto Neuroscience by 1.4% in the first quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock valued at $811,000 after purchasing an additional 490 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Alto Neuroscience by 6.3% in the first quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock valued at $2,327,000 after purchasing an additional 6,100 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Alto Neuroscience by 26.1% during the first quarter. Dimensional Fund Advisors LP now owns 39,324 shares of the company’s stock worth $884,000 after buying an additional 8,148 shares in the last quarter. GK Wealth Management LLC purchased a new position in Alto Neuroscience during the second quarter worth approximately $226,000. Finally, Wellington Management Group LLP boosted its stake in Alto Neuroscience by 18.6% during the second quarter. Wellington Management Group LLP now owns 70,913 shares of the company’s stock worth $1,871,000 after buying an additional 11,114 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with neuropsychiatric disorders. The company combines clinical data, biological measurements and digital assessments to identify patient characteristics that may help predict treatment response and guide the development of more targeted therapies.

Alto’s pipeline has included investigational treatments for conditions such as major depressive disorder and schizophrenia.